IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on IDEXX Laboratories, with six buy ratings and four holds. The average 12-month price target is $747, despite recent target revisions from Barclays, UBS, and Citigroup.
• IDEXX exceeded quarterly expectations, reporting $4.27 in EPS versus the $3.94 consensus and $1.22 billion in revenue. Revenue increased 9.7% year over year, while full-year 2026 EPS guidance is $14.69–$14.94.
• IDXX opened at $515.15, near its 52-week low of $511.16 and well below its $769.98 high. Institutional investors own 87.84% of the stock, while a company director recently sold shares worth approximately $1.17 million.

IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten research firms that are presently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $747.00.

Several equities research analysts have commented on IDXX shares. Barclays dropped their target price on IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating on the stock in a report on Tuesday, August 11th. UBS Group lifted their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 5th. Citigroup upped their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 5th. Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Finally, Weiss Ratings downgraded shares of IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday, August 27th.

Insider Activity

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the company's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director owned 9,568 shares in the company, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.79% of the company's stock.

Institutional Investors Weigh In On IDEXX Laboratories

Several institutional investors and hedge funds have recently made changes to their positions in IDXX. Aurora Investment Managers LLC. bought a new position in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $2,442,000. Elyxium Wealth LLC purchased a new position in shares of IDEXX Laboratories in the fourth quarter valued at $3,666,459,000. Prospera Financial Services Inc bought a new stake in IDEXX Laboratories in the fourth quarter worth $4,188,000. Axxcess Wealth Management LLC increased its position in IDEXX Laboratories by 312.3% in the fourth quarter. Axxcess Wealth Management LLC now owns 5,121 shares of the company's stock worth $3,465,000 after purchasing an additional 3,879 shares during the last quarter. Finally, Life Cycle Investment Partners Ltd purchased a new stake in IDEXX Laboratories during the fourth quarter valued at $47,915,000. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Price Performance

IDXX stock opened at $515.15 on Thursday. The firm has a 50 day moving average price of $557.68 and a 200-day moving average price of $567.79. IDEXX Laboratories has a 52-week low of $511.16 and a 52-week high of $769.98. The firm has a market capitalization of $40.58 billion, a price-to-earnings ratio of 36.23, a PEG ratio of 2.78 and a beta of 1.54. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter in the prior year, the business posted $3.50 EPS. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities research analysts forecast that IDEXX Laboratories will post 14.81 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.

Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.